INSIGHTS ON DRUG DEVELOPMENT

• Scale-Up Of AAV Production In Fixed-Bed Bioreactors

  Consistent AAV production is critical for manufacturing. See how aligned strategies deliver comparable cell growth, metabolic trends, and rAAV5 titers from development through production.

• Overcoming Volume And Viscosity Barriers In Biologic Formulations

  Learn how advanced containment solutions support high-viscosity biologics, improve device compatibility, enhance injection performance, and address evolving drug delivery and patient care challenges.

• Solving Formulation Challenges Across Modalities

  Optimize drug delivery by leveraging advanced nanoparticle engineering to dramatically increase small-molecule oral drug loading and enable ultra-high-concentration subcutaneous formulations.

• Cost Modeling Analysis Of AAV And LV Manufacturing

  Manufacturing scale plays a critical role in viral vector economics. Compare AAV and LV production scenarios to gain insight into how intermediate-scale strategies can reduce cost and risk.

• Solving The Inhalation Puzzle: A CDMO's Guide To Dry Powder Development

  7/9/2025

  Gain guidance on the choice of formulation, excipients, and the micronization technologies offered by CDMOs, and learn about current encapsulation technologies for inhaled products.

• Advances In Custom Medium Development: The Multi-Omics Difference

  6/9/2025

  Spent media analysis continues to be an essential part of many media development workflows. Newer techniques, however, using state-of-the-art analytical technology, are becoming more popular.

• If Collaboration Fuels Biopharma Innovation, Why Can't We Connect More?

  3/17/2026

  Breakthroughs thrive when biopharma teams work across silos, yet collaboration remains surprisingly difficult. Explore the barriers and why they persist. What will it take to move beyond them?

• Getting The Most Out Of Cell-Based Assays With The Optimal Read Function

  10/29/2025

  Gain insight into a whole-well fluorescence analysis that improves sensitivity and reproducibility in cell-based assays by accounting for uneven cell distribution.

• Delivering Critical Therapies With Speed And Safety

  6/26/2026

  Faster approvals depend on treating regulation as part of development, not the finish line. See how early quality planning and strong agency communication can move therapies toward patients sooner.